- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.04. | Notable Labs, Ltd. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 12.04. | Notable Labs reports FY results | 1 | Seeking Alpha | ||
| 12.04. | Notable Labs Reports 2023 Financial Results and Provides a Business Update | 145 | GlobeNewswire (Europe) | FOSTER CITY, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) ("Notable" or the "Company"), a clinical-stage precision oncology company developing new cancer therapies... ► Artikel lesen | |
| 12.04. | Notable Labs Ltd reports results for the quarter ended in December - Earnings Summary | 1 | Reuters | ||
| 11.04. | Notable Labs, Ltd. - 10-K, Annual Report | 1 | SEC Filings | ||
| 09.04. | Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024 | 216 | GlobeNewswire (Europe) | Poster outlines the parameters for developing a flow-cytometry-based PPMP as a companion diagnostic to predict volasertib responders, based on a proof-of-concept study using 41 primary acute myeloid... ► Artikel lesen | |
| 08.04. | Notable Labs, Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.04. | Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform | 1 | GlobeNewswire (USA) | ||
| 01.04. | Notable Labs, Ltd. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 1 | SEC Filings | ||
| 25.03. | Notable Labs, Ltd. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.03. | Notable Labs Ltd expected to post a loss of 43 cents a share - Earnings Preview | 4 | Reuters | ||
| 05.03. | Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform | 2 | GlobeNewswire (USA) | ||
| 22.02. | Notable Labs advances phase 2 trial for AML treatment | 2 | Investing.com | ||
| 22.02. | Notable Labs, Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.02. | Notable Labs, Ltd. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.01. | Pre-market Movers: Sentage Holdings, Syra Health, Grifols, Notable Labs, Juniper Networks | 593 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.05 A.M. ET).In the Green Sentage Holdings Inc. (SNTG) is up over 89% at $4.04.
Syra... ► Artikel lesen | |
| 18.12.23 | Notable Labs, Ltd. - 8-K, Current Report | 4 | SEC Filings | ||
| 18.12.23 | Notable Labs; CicloMed, LLC: Notable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial Outcome | 4 | GlobeNewswire (USA) | ||
| 04.12.23 | Notable Labs to Participate in JMP Securities Hematology and Oncology Summit | 2 | GlobeNewswire (USA) | ||
| 14.11.23 | Notable Labs Announces Filing of Form 10-Q for Third Quarter 2023 | 436 | GlobeNewswire (Europe) | -Summarizes third quarter 2023 financials of pre-Merger VBLT as of September 30th- -Third quarter financial information of Notable Labs, Inc. and pro forma combined financial information of Notable... ► Artikel lesen |
Seite:
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,940 | +0,90 % | Ihre wichtigsten Termine: Heute im Fokus: Zahlen von Porsche AG, Philips, Qiagen, Vivendi und Bawag Group | © Foto: Porsche AG NewsroomGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:55... ► Artikel lesen | |
| EVOTEC | 9,760 | -1,36 % | Evotec vor Übernahme? Ausblick 2024 im Detail | Der Versuch der Shortseller, die Evotec-Aktie (WKN: 566480) nach dem Kurssturz am vergangenen Mittwoch noch tiefer zu drücken, ist gescheitert. Die Equity Story des innovativen Hamburger Wirkstoffforschers... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 45,110 | +4,06 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates | - Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter - - Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 37,400 | +3,03 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update | KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2)... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 8,000 | -6,98 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DYNE THERAPEUTICS | 26,080 | +0,31 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights | - Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 - WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne... ► Artikel lesen | |
| NUVALENT | 70,35 | -2,95 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,840 | +0,57 % | (RXRX) - Analyzing Recursion Pharmaceuticals' Short Interest | ||
| CG ONCOLOGY | 36,270 | -8,18 % | CG Oncology Inc.: Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer | - Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today... ► Artikel lesen | |
| ANNEXON | 4,880 | +4,72 % | Annexon (ANNX) to Report Q1 Earnings: What's in the Cards? | ||
| JANUX THERAPEUTICS | 64,78 | +3,76 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
| SANA BIOTECHNOLOGY | 10,440 | +6,75 % | Sana Biotechnology, Inc: Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates | Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Early SC291 data from ongoing ARDENT trial in relapsed/refractory... ► Artikel lesen | |
| CABALETTA BIO | 12,390 | -1,67 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 27,270 | +2,83 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 26,450 | +3,40 % | Navigating 7 Analyst Ratings For Avidity Biosciences |
NOTABLE LABS LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,05 % bei einem Aktienkurs von 0,940 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
